- Home
- CRSP vs VEON Comparison
CRSP vs VEON Comparison
Compare CRSP & VEON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRSP
- VEON
- Stock Information
- Founded
- CRSP 2013
- VEON 1992
- Country
- CRSP Switzerland
- VEON United Arab Emirates
- Employees
- CRSP 393
- VEON N/A
- Industry
- CRSP Biotechnology: Biological Products (No Diagnostic Substances)
- VEON Telecommunications Equipment
- Sector
- CRSP Health Care
- VEON Telecommunications
- Exchange
- CRSP Nasdaq
- VEON Nasdaq
- Market Cap
- CRSP 3.3B
- VEON 3.0B
- IPO Year
- CRSP 2016
- VEON 1996
- Fundamental
- Price
- CRSP $35.62
- VEON $46.84
- Analyst Decision
- CRSP Buy
- VEON Strong Buy
- Analyst Count
- CRSP 17
- VEON 1
- Target Price
- CRSP $74.53
- VEON $60.00
- AVG Volume (30 Days)
- CRSP 2.0M
- VEON 124.6K
- Earning Date
- CRSP 05-06-2025
- VEON 05-15-2025
- Dividend Yield
- CRSP N/A
- VEON N/A
- EPS Growth
- CRSP N/A
- VEON N/A
- EPS
- CRSP N/A
- VEON 5.75
- Revenue
- CRSP $37,675,000.00
- VEON $4,004,000,000.00
- Revenue This Year
- CRSP $51.35
- VEON $5.99
- Revenue Next Year
- CRSP $282.16
- VEON $7.19
- P/E Ratio
- CRSP N/A
- VEON $8.33
- Revenue Growth
- CRSP N/A
- VEON 8.28
- 52 Week Low
- CRSP $30.04
- VEON $24.50
- 52 Week High
- CRSP $67.88
- VEON $48.70
- Technical
- Relative Strength Index (RSI)
- CRSP 44.74
- VEON 59.66
- Support Level
- CRSP $33.03
- VEON $43.81
- Resistance Level
- CRSP $39.38
- VEON $46.48
- Average True Range (ATR)
- CRSP 1.81
- VEON 2.12
- MACD
- CRSP -0.19
- VEON 0.38
- Stochastic Oscillator
- CRSP 33.64
- VEON 62.93
About CRSP CRISPR Therapeutics AG
Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.
About VEON VEON Ltd. ADS
VEON Ltd is a digital operator that provides connectivity and digital services to nearly 160 million customers. The group operates across six countries that are home to more than 7% of the world's population. The company is transforming lives through technology-driven services that empower individuals and drive economic growth.